Today many universities have a mandate to preferentially create new companies around university technologies, rather than stick with straight licensing deals, particularly when it comes to medical devices. What's also new is that universities are making a concerted effort to attract in companies from beyond their hallowed gates to enhance internal research programs. To meet these goals, they're turning to new kinds of incubators, which are essentially service organizations that connect resources in the hands of multiple constituencies to start-up companies. In so doing, incubators are facilitating the process of company creation for individual entrepreneurs, enhancing university tech transfer, and fulfilling regional economic development goals.
Mary Stuart
Stanford. MIT. Harvard. The Hutch. The names of the universities capable of spinning off high-quality life science companies are well known to investors, entrepreneurs, and business development folks alike. But...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.
Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.
